Uniphar PLC · EURONEXT:UPR
Uniphar — Webinar 12 (October 2017)
21 slides from Uniphar's conference presentation, October 2017

Slide 1: ProVen: Probiotics for Childhood Allergies, Coughs & Colds
Webinar 12 ProVen: Probiotics for Childhood Allergies, Coughs & Colds

Slide 2: Antibiotics In Early Life And Risk Of Childhood Allergy
ProVen Antibiotics In Early Life And Risk Of Childhood Allergy Eczema Postnatal ( 2 week post birth) antibiotic exposure was associated with a 40% increased risk of eczema, with further 7% increased risk for each additional antibiotic course received during the first year of life (OR= 1.41, 95%CI: 1

Slide 3: Probiotics in the Prevention of Childhood Allergy
ProVen Probiotics in the Prevention of Childhood Allergy • Type 1 hypersensitivity effects approximately 20% of children • Almost all allergy established in first 2 years of life • First expression is atopic eczema, followed by asthma, and rhinitis – the ‘allergic march’ • Meta analyses of 11 infant

Slide 4: Swansea Baby Study - Allergy Prevention Trial
ProVen Swansea Baby Study - Allergy Prevention Trial AIM Investigate the effect of probiotics on prevention of allergic sensitization and allergic eczema in infants STUDY DESIGN: DBPC study with 454 mother-infant pairs ProVen Pregnancy provided to mothers in 3rd trimester and ProVen Baby provided to

Slide 5: Atopic eczema in infant
ProVen Atopic eczema in infant

Slide 6: PROBAT Study: Probiotics in Prevention of Allergy
ProVen PROBAT STUDY: PROBIOTICS IN PREVENTION OF ALLERGY Allen SJ et al. Archives of Disease in Childhood 2014 Jun 19; doi:10.1136/archdischild-2013-305799

Slide 7: Swansea Study Demonstrated Safety Of ProVen Probiotics in Mothers and Newborns
ProVen Swansea Study Demonstrated Safety Of ProVen Probiotics in Mothers and in Newborns ProVen Pregnancy and ProVen Baby administration was not associated with adverse events in either mothers or their infants.

Slide 8: Swansea Baby Trial – Clinical Outcomes
ProVen Swansea Baby Trial – Clinical Outcomes Significant Reduction in Atopic Sensitisation in Children of 6 and 24 Months Atopic sensitisation measured by skin prick test reaction to one or more of following allergens: cows milk, egg, grass pollen, tree pollen, house dust mite, nuts, fish.

Slide 9: Effect of Lab4b Probiotics on Incidence of Atopic Eczema
ProVen The Effect of Lab4b Probiotics on Incidence of Atopic Eczema at 6 and 24 Months From Birth Atopic eczema defined as SCORAD measurement of skin rash co presented with SPT positivity for at least one allergen. 14 Atopic eczema in 12 * infants (%) 10 8 * Placebo 6 Probiotic 4 2 0 6 months 2 year

Slide 10: Coughs and Colds – we all get 'em!
ProVen Coughs and Colds – we all get ‘em! Coughs and colds – or upper respiratory tract infections ( UTRI) – are the most common infections we experience – adults 2-3 episodes per year: children 3-8 episodes per year. Symptoms: Most common cause of: • sore throat • days off work • runny or blocked n

Slide 11: Are Probiotics More Effective Than Vitamin C and Zinc
ProVen Are Probiotics More Effective Than Vitamin C and Zinc in Prevention of Coughs and Colds Recent Cochrane meta-analysis concluded that vitamin C at doses above 200mg/day: - reduced duration of coughs and colds in adults by average of 8% - reduced duration of coughs and colds in children by 14%

Slide 12: PROCHILD Study
ProVen PROCHILD Study AIM: To assess the impact of the combination of LAB4 probiotics with vitamin C on upper respiratory tract infections in children attending preschool facilities. STUDY DESIGN: Randomised double blind placebo controlled study : 57 children aged between 4-6 years provided with Pro

Slide 13: PROCHILD Study: Probiotics in the prevention of coughs and colds
ProVen PROCHILD STUDY: Probiotics in the prevention of coughs and colds Garaiova I et al. European Journal of Clinical Nutrition 2014 Sept 10; doi:10.1038/ejcn.2014.174

Slide 14: PROCHILD Study – Main Results
ProVen PROCHILD Study – Main Results • Total number of days with URTI symptoms (sneezing, sore throat, cough, runny/blocked nose 51% reduction in active group (p= 0.0059) • Frequency of occurrence of URTI symptoms 33% reduction in active group (p= 0.0019) • Absence from preschool 30% reduction in ac

Slide 15: ProVen Reduces Duration of URTI Symptoms by 50%
ProVen Reduces Duration of UTRI Symptoms by 50% Total Number of Days with URTI * 45 40 Symptoms 35 30 P = 0.07 * 25 20 15 10 5 0 Sneezing Runny nose Blocked nose Sore throat Cough Total URTI Placebo symptoms

Slide 16: ProVen Reduces Incidence of URTI Symptoms by 33%
ProVen Reduces Incidence of URTI Symptoms by 33%

Slide 17: ProVen Reduces Absenteeism from School by 30%
ProVen Reduces Absenteeism from School by 30% Total Number of Days Absent from Preschool Facilities P = 0.007 P=0.0069 20 15 10 5 0 Due to URTI Any Illness Placebo Lab4+Vitamin C

Slide 18: Total Medication Reduced by 50%
ProVen Total Medication Reduced by 50% Total Number of Days of 50 40 Medication Usage 30 20 * 10 0 Cough medicine Antihistamins Nasal spray/drops Painkillers Total Placebo Lab4+Vitamin C

Slide 19: Visits to Physician Reduced by 50%
ProVen Visits to Physician Reduced by 50% Total Number of Physician P = 0.08 Visits 3.5 3 2.5 2 1.5 1 0.5 0 Due to URTI Any Illness Placebo Lab4+Vitamin C

Slide 20: ProVen Reduce Antibiotic Use by 40%
ProVen Reduce Antibiotic Use by 40% NUMBER OF CHILDREN WITH A LEAST ONE DAY OF ORAL ANTIBIOTIC USE Placebo Lab4+Vitamin C 25 20 15 10 24.1 5 14.3 0 Number of children (%)

Slide 21: ProVen: The Gut-Brain Axis
e Link Vitamins, Minerals ++ P roVe n up and Supplements The Gut-Brain Axis Se 6 | &suniphar retail services
Source: Internet Archive copy of uniphar.ie
More decks from Uniphar PLC
H1 2026 Earnings Presentation39 slides · Sep 8, 2026
FY2025 Earnings Presentation39 slides · Feb 24, 2026
FY2024 Earnings Presentation38 slides · Feb 25, 2025
H1 2024 Earnings Presentation37 slides · Sep 3, 2024
FY2023 Earnings Presentation39 slides · Feb 27, 2024
H1 2023 Earnings Presentation41 slides · Sep 14, 2023